SCHEMBL7141075

SCHEMBL7141075

O=S(=O)(c1ccc(Cl)cc1)N(CCc1ccccc1)C1CCN(Cc2ccccc2)CC1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.56
PSEN1 P49768 4/20 0.55
PSEN2 P49810 4/20 0.55
APH1B Q8WW43 4/20 0.55
NCSTN Q92542 4/20 0.55
APH1A Q96BI3 4/20 0.55
PSENEN Q9NZ42 4/20 0.55
OPRM1 P35372 1/20 0.51
CHRM2 P08172 3/20 0.50
CHRM3 P20309 3/20 0.50
ALDH1A1 P00352 2/20 0.50
CYP2D6 P10635 1/20 0.50
BACE1 P56817 3/20 0.48
HTR2A P28223 1/20 0.48
SIGMAR1 Q99720 1/20 0.47
BCHE P06276 1/20 0.46
ACHE P22303 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7142813 0.93 HTR2A (0.56) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL7141347 0.91 CHRM4 (0.52) HTTPSEN1PSEN2APH1BNCSTN
SCHEMBL7141098 0.90 OPRM1 (0.53) OPRM1CHRM2CHRM3ALDH1A1BACE1
SCHEMBL1682312 0.82 HTT (0.54) HTTPSEN1PSEN2APH1BNCSTN
SCHEMBL2336394 0.81 HTT (0.53) HTTCHRM2CHRM3ALDH1A1CYP2D6
SCHEMBL7140154 0.81 HTT (0.58) HTTOPRM1CHRM2CHRM3ALDH1A1
SCHEMBL14045066 0.81 HTR6 (0.48) HTTOPRM1CHRM2CHRM3ALDH1A1
SCHEMBL7146866 0.80 LMNA (0.54) HTTPSEN1PSEN2APH1BNCSTN
SCHEMBL16757144 0.76 KMT2A (0.69) OPRM1CHRM2CHRM3ALDH1A1BACE1
SCHEMBL2337985 0.75 ALDH1A1 (0.52) HTTPSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176461-A1 Aminopiperidines NPS ALLELIX CORP. (CANADA CORPORATION) (CA) 2003-09-18 US claimed
EP-1296950-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS Allelix Corp. (CA) 2003-04-02 EP claimed
WO-2001081308-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS ALLELIX CORP. (CA) 2001-11-01 WO claimed
US-20030176461-A1 Aminopiperidines NPS ALLELIX CORP. (CANADA CORPORATION) (CA) 2003-09-18 US disclosed
EP-1296950-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS Allelix Corp. (CA) 2003-04-02 EP disclosed
WO-2001081308-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS ALLELIX CORP. (CA) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176461-A1 Aminopiperidines SLC1A2, SLC6A4, SLC1A1 HTT 315/4885PSEN1 154/4885PSEN2 182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.